Alzamend Neuro announced Phase II trial results showing AL001, a new lithium formulation, achieves bioequivalence with standard lithium carbonate in blood exposure while delivering higher lithium levels across all brain regions. AL001 reached peak brain lithium concentration faster (6.7 hours vs. 8.4 hours), potentially improving therapeutic effects for Alzheimer's, bipolar disorder, depression, and PTSD. The trial used advanced MRI technology to measure lithium in 26 brain regions. A second Phase II trial in bipolar patients is underway, with more studies planned for other conditions in 2026. These results support AL001's potential as a safer, more effective lithium therapy with faster brain uptake and better brain targeting.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
